Further investigation of IHC from clinical melanoma patients revealed significantly elevated expression of TRIM22 in stage II and stage III tumors (Fig. 1F, G), corroborating our initial finding of a direct association of TRIM22 with tumor stage. This evidence concerns the gene TRIM22 and neoplasm.